Key Takeaways from the BIO International Convention 2022
Nicole Brenna, US Business Development Director, represented Cromos Pharma at the BIO Intenational Convention. Please read her key takeaways from the event.
“This was my first BIO conference in person and it was great meeting Sponsors and our partners from all over the world. It was definitely nice to finally shake hands and exchange business cards, as everything over the last two years has been virtual.
The BIO One-on-One Partnering was very beneficial as it allowed for individuals to speak one-on-one for 30 minutes without interruption. I have noticed in the past at conferences, it can be quite difficult to find a quiet place to speak about study details without others hearing, so the individual partnering rooms was the perfect solution.
There was a lot of discussion around patient diversity in clinical trials and the importance of including this in studies. Decentralized clinical trials continues to be a hot topic, as we slowly come out of the pandemic. I spoke with a lot of Sponsors who are working in the rare disease space and they stressed how enrollment can be quite challenging. With that being said, it was great to hear Venus Williams speak about her personal struggle with having a rare disease and how she functions daily and keeps a positive outlook on life,” said Nicole Brenna.
About Cromos Pharma
Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic areas. Our expert team, comprising 95% MDs, has expansive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
Cromos Pharma has experience in delivering success in studies from biosimilars and generics to successfully managing oncology, neurology, and dermatology clinical trials. Our team provides full-service solutions to international pharma and biotech in high-recruiting regions, assuring exceptional quality data. Cromos Pharma combines global expertise, with in-depth experience and knowledge, in Central and Eastern Europe to offer exceptional patient recruitment. Our team has met or reduced enrollment timelines in 95% of trials conducted.
We provide accelerated study start-up timelines in our regions of operation. We regularly achieve regulatory approvals in Georgia within two months of project signing. Regulatory inspections and site audits also attest to the highest quality of our clinical data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection).
Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is located in Portland, Oregon, USA and European HQ in Dublin, Ireland.